StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Guanethidin

Guanethidine

HCID 3518
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
55-65-2
Standard-SMILES
NC(N)=NCCN1CCCCCCC1
InChIKey
ACGDKVXYNVEAGU-UHFFFAOYSA-N
Summenformel
C10H22N4
Durchschnittliche Molmasse
198,31 g/mol
Monoisotopische Masse
198,1844467

Überblick

Guanethidine is a member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group. It has a role as an antihypertensive agent, an adrenergic antagonist and a sympatholytic agent. It is a member of guanidines and a member of azocanes. It is functionally related to a guanidine. It derives from a hydride of an azocane.

Namen und Bezeichner

Bevorzugter Name
Guanethidine
IUPAC
2-[2-(azocan-1-yl)ethyl]guanidine
Lokaler Name
Guanethidin
Englischer Name
guanethidine
Summenformel
C10H22N4
Molmasse
198.31

Namen und Synonyme

GUANETHIDINE55-65-2AbapresinSanotensinEutensolOktadinOctatensineOktatensinOktatenzinDopomGuanetidinaOctadine
Weitere Namen anzeigen
C07036guanethidine USP/EP/BP1-(2-perhydroazocin-1-ylethyl)guanidineN-[2-(Octahydroazocin-1-yl)ethyl]guanidine
Guanethidinum2-(1'-Azacyclooctyl)ethylguanidineN-(2-Perhydroazocin-1-ylethyl)guanidineAzocine, 1-(2-guanidinoethyl)octahydro-2-[2-(azocan-1-yl)ethyl]guanidine2-(1-N,N-Heptamethyleneimino)ethylguanidineGuanidine, (2-(hexahydro-1(2H)-azocinyl)ethyl)-(2-(Octahydro-1-azocinyl)ethyl)guanidine

Datenbank-Bezeichner

CAS
55-65-2、645-43-2
PubChem CID
3518
DTXSID
DTXSID5023116
ChEMBL
CHEMBL765
ChEBI
CHEBI:5557
UNII
ZTI6C33Q2Q
EC Number
200-241-3
Nikkaji
J4.562D

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
0,5
Polarare Oberfläche (TPSA)
67,6 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
3
Schwere Atome
14
Formalladung
0
Komplexität
167

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP0.8
Solubility · 4 Einträge

Very soluble

WHITE, CRYSTALLINE POWDER; STRONG CHARACTERISTIC ODOR; SPARINGLY SOL IN WATER; SLIGHTLY SOL IN ALC; PRACTICALLY INSOL IN CHLOROFORM /SULFATE/

WHITE, CRYSTALLINE POWDER; VERY SOL IN H2O; INSOL IN NONPOLAR SOLVENTS /MONOSULFATE/

2.25e+00 g/L

Human DrugsPharmaceuticals
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point · 2 Einträge

276-281

250 °C (sulfate salt)

Physical DescriptionSolid
Collision Cross Section151.79 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Other Experimental PropertiesCRYSTALS FROM DIL ETHANOL; MP 276-281 °C (DECOMP) /SULFATE/

Physikochemische Eigenschaften

Siedepunkt
325.64 °C · 325.64°C (rough estimate)
Dichte
0.9402 · 0.9402 (rough estimate)
Brechungsindex
1.491 · 1.4910 (estimate)
storage temp.
-20 °C · Store at -20°C
pka
11.4 · pKa 11.4 (Uncertain)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Gefahrenhinweise

Other Safety InformationIMAP assessments - Guanidine, [2-(hexahydro-1(2H)-azocinyl)ethyl]-: Environment tier I assessment

Toxikologische Informationen

Interactions · 5 Einträge

MONOAMINE OXIDASE INHIBITORS HAVE BEEN REPORTED TO ANTAGONIZE ANTIHYPERTENSIVE EFFECTS OF GUANETHIDINE.

TOPICALLY ADMIN GUANETHIDINE ENHANCES RESPONSE OF EYE TO TOPICALLY ADMIN PHENYLEPHRINE, RESULTING IN INCR MYDRIASIS.

THIAZIDES ENHANCE ANTIHYPERTENSIVE ACTION OF GUANETHIDINE, ALLOWING DOSE OF GUANETHIDINE TO BE REDUCED & DECR INCIDENCE OF ADVERSE REACTIONS...

ANTIHYPERTENSIVE ACTION OF GUANETHIDINE MAY BE BLOCKED BY DEXTROAMPHETAMINE & RELATED COMPD; THEREFORE, CONCURRENT USE OF THESE DRUGS SHOULD BE AVOIDED.

For more Interactions (Complete) data for GUANETHIDINE (10 total), please visit the HSDB record page.

Human Toxicity Excerpts · 5 Einträge

SOME TENDENCY TO DIARRHEA IS ASSOC WITH GUANETHIDINE THERAPY IN HIGH PERCENTAGE OF CASES... INHIBITION OF EJACULATION IS COMMON, & IMPOTENCE MAY BE PSCHOGENIC AFTERMATH. ...CAN CAUSE SEVERE HYPERTENSIVE REACTIONS IN PT WITH PHEOCHROMOCYTOMA.

HYPOTENSIVE EPISODES MAY BE ASSOC WITH SYMPTOMS OF CEREBRAL & MYOCARDIAL ISCHEMIA. ... GENERALIZED SUBJECTIVE "WEAKNESS" IS COMMON... FLUID RETENTION OCCURS & CAN LEAD TO EDEMA & RESISTANCE TO ANTIHYPERTENSIVE EFFECT IF DIURETIC IS NOT GIVEN CONCURRENTLY. ...CAN LEAD TO...HEART FAILURE IN PT WITH LIMITED CARDIAC RESERVE.

MOST IMPORTANT COMPLICATION OF GUANETHIDINE THERAPY IS POSTURAL HYPOTENSION; IT IS MOST PROMINENT SHORTLY AFTER ARISING FROM SLEEP & MAY BE ACCENTUATED BY HOT WEATHER, ALCOHOL, OR EXERCISE.

APPLICATION OF 5%-10% GUANETHIDINE SULFATE SOLN TO EYES OF PT HAS INDUCED SLIGHT MIOSIS, NOTICEABLE PTOSIS & HYPEREMIA FROM ANTIADRENERGIC ACTION. ... 50% OF PT WITH THYROID DYSFUNCTION & EXOPHTHALMOS HAVE DEVELOPED SUPERFICIAL CHANGES IN CORNEAL EPITHELIUM AFTER 1-8 WK OF APPLYING SOLN TWICE DAY. /SULFATE/

For more Human Toxicity Excerpts (Complete) data for GUANETHIDINE (9 total), please visit the HSDB record page.

Drug Induced Liver Injury · 6 Einträge

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

guanethidine

Ismelin®

Antiadrenergics

Not Applicable

no-DILI-concern

Sicherheitsdaten

Toxizität
LD50 oral in rat: 1050mg/kg
Giftige Stoffe Daten
55-65-2(Hazardous Substances Data)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

S - Sensory organs

C - Cardiovascular system

QS - Sensory organs

QC - Cardiovascular system

Pharmacodynamics · 1 Eintrag

High blood pressure can cause the heart and arteries to not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled. Guanethidine works by decreasing the heart rate and relaxing the blood vessels so that blood can flow more easily through the body, thereby reducing these risks. It is a postganglionic sympathetic nerve terminal blocker that prevents the release of norepinephrine from nerve terminals.

Mechanism of Action · 6 Einträge

Guanethidine acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine (NE), rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters to be concentrated within the transmitter vesicles in place of NE, leading to gradual depletion of NE stores in the nerve endings. Guanethidine at the nerve terminal blocks the release of noradrenaline in response to an action potential. In contrast to ganglionic blocking agents, Guanethidine suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, Guanethidine lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.

GUANETHIDINE MAY BE CONSIDERED REPRESENTATIVE OF DRUGS THAT DEPRESS FUNCTION OF POSTGANGLIONIC ADRENERGIC NERVES.

RAPID IV INJECTION...PRODUCES...INITIAL RAPID FALL IN BLOOD PRESSURE ASSOC WITH INCR CARDIAC OUTPUT & DECR PERIPHERAL RESISTANCE; LATTER IS PROBABLY DUE TO TRANSIENT DIRECT ACTION OF DRUG ON RESISTANCE VESSELS. FALL IN BLOOD PRESSURE IS FOLLOWED BY HYPERTENSION...

MAJOR EFFECT...INHIBITION OF RESPONSES TO SYMPATHETIC ADRENERGIC NERVE ACTIVATION & TO INDIRECT-ACTING SYMPATHOMIMETIC AMINES. SINCE GUANETHIDINE ALSO SENSITIZES EFFECTOR CELLS TO CATECHOLAMINES, EFFECTIVE BLOCK MUST MEAN THAT AMT OF MEDIATOR RELEASED IS DRASTICALLY REDUCED. ...HAS CONSIDERABLE LOCAL ANESTHETIC ACTIVITY...

GUANETHIDINE APPARENTLY ACCUMULATES IN & DISPLACES NOREPINEPHRINE FROM INTRANEURONAL STORAGE GRANULES, & IS ITSELF RELEASED BY NERVE STIMULATION. THUS IT FITS DEFINITION OF "FALSE TRANSMITTER" BUT THIS MECHANISM APPEARS NOT TO BE RESPONSIBLE FOR ITS EFFECTS.

For more Mechanism of Action (Complete) data for GUANETHIDINE (7 total), please visit the HSDB record page.

Biological Half-Life · 2 Einträge

1.5 days

...GUANETHIDINE...IS BOUND TO PLASMA PROTEINS & TISSUES, CAUSING PROLONGED T/2 OF ABOUT 30 HR.

Metabolism/Metabolites · 4 Einträge

Guanethidine is converted by the liver to three metabolites, which are excreted in the urine. The metabolites are pharmacologically less active than the parent compound.

METABOLISM APPEARS TO BE BY HEPATIC MICROSOMAL ENZYMES, & PERCENTAGE METABOLIZED IS CONSIDERABLY HIGHER AFTER ORAL THAN AFTER PARENTERAL ADMIN.

...TERTIARY NITROGEN OF PERHYDROAZOCINE RING UNDERGOES N-OXIDATION TO SIGNIFICANT EXTENT IN MAN.

HYPOTENSIVE PT ON GUANETHIDINE ELIMINATED VIA KIDNEYS UNCHANGED, ALSO GUANETHIDINE N-OXIDE, & 2-(6-CARBOXYHEXYLAMINO)-ETHYLGUANIDINE.

MeSH Pharmacological Classification · 3 Einträge

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Absorption, Distribution and Excretion · 6 Einträge

3-30% of oral dose (poor and highly variable)

Ismelin is converted by the liver to three metabolites, which are excreted in the urine.

Renal cl=56 ml/min

...30 MIN AFTER IP ADMIN OF [(14)C]-GUANETHIDINE, ANTIHYPERTENSIVE AGENT, TO MICE, MOST OF [(14)C] WAS DISTRIBUTED IN LIVER, GI TRACT, SPLEEN, KIDNEYS, URINARY BLADDER, SALIVARY GLANDS, & BROWN FAT. IN RAT, LEVELS...IN PLASMA WERE LOWER THAN IN TISSUES...1-2 HR AFTER IP ADMIN.

HUMAN SUBJECTS RECEIVING GUANETHIDINE, HAD EXCRETED 24% OF [(14)C] IN URINE 24 HR AFTER ORAL DOSE, & 52% AFTER IV DOSE. EXCRETION OF (14)C CONTINUED, & ABOUT HALF AMT EXCRETED IN 24 HR WAS PRESENT IN URINE AFTER FURTHER 48 HR. IN 72 HR ABOUT 23% WAS EXCRETED IN FECES AFTER ORAL DOSE & 3% AFTER IV DOSE.

MUCH OF IV DOSE OF [(3)H]GUANETHIDINE WAS EXCRETED UNCHANGED IN URINE OF HUMAN HYPERTENSIVE SUBJECTS; MORE SLOWLY FROM THOSE SUFFERING ADDITIONALLY FROM RENAL FAILURE.

Cellular LocationsMembrane

Verwendung und Herstellung

UsesMEDICATION
Methods of ManufacturingMAXWELL ET AL, EXPERIENTIA 15, 267 (1959); MULL, US PATENT 2,928,829 (1960 TO CIBA). IMPROVED PROCESS: MULL, US PATENTS 3,006,916; 3,055,882 (1961, 1962 TO CIBA).
Formulations/Preparations · 2 Einträge

GUANETHIDINE SULFATE, USP (ISMELIN), IS AVAILABLE IN 10- & 25-MG TABLETS FOR ORAL ADMIN. /SULFATE/

...MARKETED ONLY IN 10:25 COMBINATION WITH HYDROCHLOROTHIAZIDE. /MONOSULFATE/

Use ClassificationPharmaceuticals
Anwendungen · 3 Einträge

BeschreibungGuanethidine is used for severe hypertension when the use of the more generally accepted drugs turns out to be unsuccessful. It is a powerful, long-lasting antihypertensive drug; however, it affects a patient’s blood pressure only in the orthostatic position, and not when lying down. Guanethidine is a very powerful and long-lasting drug, and its action often lasts 2–3 days after its use has been stopped.

VerwendenGuanethidine is used for severe hypertension, where use of more universally accepted drugs is not successful. It is a very powerful and long-lasting drug, and its effects last for 2–3 days after using it.

VerwendenAntihypertensive.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

MethylthioharnstoffWasserPerhydroazociniso-MalathionN-2-BromethylphthalimidNatriumcarbonatSchwefelsureLithium Aluminum Hydride

Ergänzende Hinweise

DefinitionChEBI: A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.

Zugehörige Reaktionen

8
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 516270
HRID 516270als Produkt
Reaktionsgleichung von HRID 531403
HRID 531403als Produkt
Reaktionsgleichung von HRID 634083
HRID 634083als Produkt
Reaktionsgleichung von HRID 707734
HRID 707734als Produkt
Reaktionsgleichung von HRID 924542
HRID 924542als Produkt
Reaktionsgleichung von HRID 1402617
HRID 1402617als Produkt
Reaktionsgleichung von HRID 1754016
HRID 1754016als Produkt
Reaktionsgleichung von HRID 2170237
HRID 2170237als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung